Guggenheim Begins Coverage on Celcuity (NASDAQ:CELC)

Research analysts at Guggenheim assumed coverage on shares of Celcuity (NASDAQ:CELC) in a research report issued to clients and investors on Friday, MarketBeat Ratings reports. The firm set a “buy” rating and a $169.00 price target on the stock. Guggenheim‘s price target points to a potential upside of 153.03% from the stock’s previous close.

A number of other brokerages have also recently commented on CELC. Wall Street Zen cut shares of Celcuity from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Stifel Nicolaus lowered their price objective on Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Citizens Jmp reissued a “market outperform” rating and issued a $177.00 target price on shares of Celcuity in a report on Monday, August 17th. Royal Bank Of Canada downgraded Celcuity to a “neutral” rating in a research report on Wednesday, October 28th. Finally, Cantor Fitzgerald assumed coverage on Celcuity in a research report on Thursday, October 22nd. They issued an “overweight” rating and a $140.00 price target on the stock. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $152.14.

Celcuity Price Performance

Shares of CELC stock traded up $2.75 during mid-day trading on Friday, reaching $66.79. The company’s stock had a trading volume of 1,081,623 shares, compared to its average volume of 1,806,096. Celcuity has a 1-year low of $53.54 and a 1-year high of $151.02. The company has a market cap of $3.27 billion, a P/E ratio of -14.18 and a beta of 0.16. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 8.93. The firm’s 50-day moving average is $75.11 and its two-hundred day moving average is $99.38.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, November 5th. The company reported ($1.21) EPS for the quarter, topping analysts’ consensus estimates of ($1.51) by $0.30. On average, research analysts predict that Celcuity will post -4.98 earnings per share for the current year.

Institutional Trading of Celcuity

Several large investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. raised its stake in shares of Celcuity by 685.9% in the third quarter. Assenagon Asset Management S.A. now owns 1,478,607 shares of the company’s stock valued at $117,579,000 after acquiring an additional 1,290,466 shares during the last quarter. Bank of America Corp DE bought a new stake in Celcuity during the 2nd quarter worth approximately $153,928,000. Wellington Management Group LLP increased its holdings in Celcuity by 111.4% during the 2nd quarter. Wellington Management Group LLP now owns 906,595 shares of the company’s stock valued at $94,848,000 after purchasing an additional 477,643 shares in the last quarter. Pictet Asset Management Holding SA increased its holdings in Celcuity by 10,659.7% during the 3rd quarter. Pictet Asset Management Holding SA now owns 291,049 shares of the company’s stock valued at $23,144,000 after purchasing an additional 288,344 shares in the last quarter. Finally, Jennison Associates LLC raised its position in Celcuity by 0.6% in the 1st quarter. Jennison Associates LLC now owns 231,140 shares of the company’s stock valued at $26,382,000 after purchasing an additional 1,436 shares during the last quarter. 63.33% of the stock is owned by institutional investors.

Key Stories Impacting Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Celcuity reported a third-quarter loss of $1.21 per share, narrower than analysts’ expected loss of $1.51. The earnings beat may support sentiment. MarketBeat earnings report
• Positive Sentiment: The Q3 earnings-call summary highlighted strong launch momentum for Revtorpic, a potential positive commercial catalyst. Q3 2026 earnings-call highlights
• Positive Sentiment: Guggenheim kept its Buy rating and lowered its price target only modestly, from $171 to $169; the report cited substantial upside relative to the referenced share price. TickerReport article
• Negative Sentiment: Celcuity’s Q3 adjusted loss widened, a counterpoint to the per-share earnings beat and a reminder that the company remains loss-making. Celcuity Q3 adjusted loss widens

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company developing functional diagnostic tests designed to help identify cancer treatments that may be most effective for individual patients. Its technology analyzes living tumor cells taken from patients to measure how signaling pathways respond to different therapies, with the goal of supporting more personalized treatment decisions.

The company’s CELsignia platform is designed to assess the activity of cancer-related signaling pathways in patient-derived cells.